{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:57:26Z","timestamp":1759481846127,"version":"3.44.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.kint.2019.02.037","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T05:01:44Z","timestamp":1560920504000},"page":"19-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["What can copeptin tell us in patients with autosomal dominant polycystic disease?"],"prefix":"10.1016","volume":"96","author":[{"given":"Lise","family":"Bankir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.02.037_bib1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1053\/j.ajkd.2015.01.030","article-title":"Total kidney volume in autosomal dominant polycystic kidney disease: a biomarker of disease progression and therapeutic\u00a0efficacy","volume":"66","author":"Alam","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.02.037_bib2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneph.2016.135","article-title":"The importance of total kidney volume in evaluating progression of polycystic kidney disease","volume":"12","author":"Grantham","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.kint.2019.02.037_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"van Gastel","year":"2017","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.kint.2019.02.037_bib4","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.02.037_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","article-title":"Plasma copeptin levels predict disease progression and tolvaptan\u00a0efficacy in autosomal dominant polycystic kidney disease","volume":"96","author":"Gansevoort","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.037_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrneph.2013.22","article-title":"Vasopressin: a novel target for the prevention and retardation of kidney disease?","volume":"9","author":"Bankir","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2019.02.037_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.037_bib8","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.02.037_bib9","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819303266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819303266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:54:10Z","timestamp":1758761650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819303266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0085253819303266"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.02.037","relation":{},"ISSN":["0085-2538"],"issn-type":[{"type":"print","value":"0085-2538"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What can copeptin tell us in patients with autosomal dominant polycystic disease?","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.02.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.11.044","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}